Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Zacks News
5 Stocks Trading Near 52-Week High With More Room to Run
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
Is Abbott Laboratories (ABT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ABT) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: Abbott, Netflix, Philip Morris, United Technologies and Novartis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott, Netflix, Philip Morris, United Technologies and Novartis
Top Research Reports for Abbott, Netflix & Philip Morris
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Abbott (ABT), Netflix (NFLX) and Philip Morris (PM).
Company News for Jul 18, 2019
by Zacks Equity Research
Companies In The News Are: ABT, USB, ERIC, TXT
IVD Market Sustains Momentum: 3 Stocks in Focus
by Trina Mukherjee
In-vitro Diagnostics has successfully proven itself to be the best diagnostic procedures. So, investors can add stocks from this space to their watchlist.
Abbott (ABT) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Abbott (ABT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Abbott (ABT) Tops Q2 Earnings Estimates, Lifts EPS Guidance
by Zacks Equity Research
Abbott (ABT) registers strong Cardiovascular and Neuromodulation sales on double-digit growth in Electrophysiology, Heart Failure and Structural Heart.
Mixed Housing Data for June
by Zacks Equity Research
Mixed Housing Data for June
Housing Starts, Building Permits Mixed; Q2 for BAC, USB, ABT
by Mark Vickery
Housing Starts were up slightly for June, but Building Permits disappointed.
Abbott (ABT) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 2.50% and -0.10%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
US-India Trade Tensions Rise: 3 Stocks in the Line of Fire
by Sreyoshi Mukherjee
As India moves toward self-sufficiency, U.S. MedTech bigwigs fret over possible losses.
5 Stocks with Spectacular Earnings Charts
by Tracey Ryniec
These companies aren't just beating on earnings, their stocks are also on fire, hitting new 5-year highs.
Abbott MitraClip G4 Gets FDA Nod, Valve Repair Options Expand
by Zacks Equity Research
The FDA approval for MitraClip G4 is expected to enhance Abbott's (ABT) cardiac treatment portfolio.
Will Abbott's (ABT) Q2 Earnings Gain From Overall Growth?
by Zacks Equity Research
Abbott's (ABT) consistent rise on a strong Diabetes Care business performance is seen over the last few quarters.
ABT or BIO: Which Stock Has Better Potential Right Now?
by Zacks Equity Research
Abbott (ABT) scores higher than Bio-Rad (BIO) in terms of valuation and one-year price performance.
Bull of the Day: Penumbra (PEN)
by Kevin Cook
This $6 billion innovator removes blood clots and the deadly shadow of stroke with catheter-based aspiration technologies
Abbott (ABT) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $83.69, moving +0.88% from the previous trading session.
Abbvie Decides to Acquire Allergan
by Zacks Equity Research
Abbvie Decides to Acquire Allergan
AbbVie to Buy Botox-Maker Allergan, Look Ahead to G-20
by Mark Vickery
AbbVie (ABBV) has agreed to purchase Botox maker Allergan (AGN) for roughly $63 billion in cash and stock.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $83.42 in the latest trading session, marking a +1.67% move from the prior day.
Abbott (ABT) Hits New 52-Week High on Solid Growth Drivers
by Zacks Equity Research
Abbott (ABT) gains from expansion of product portfolio and several regulatory clearances.
Abbott (ABT) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Abbott (ABT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $81.24, marking a +0.62% move from the previous day.